Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Febuxostat 80 mg
DRUG
3 trials
Sponsors
Ardea Biosciences, Inc.
, Ain Shams University
, JW Pharmaceutical
Conditions
Chronic Kidney Disease stage3
Contrast-induced Nephropathy
Gout
Phase 2
RDEA3170 and Febuxostat Combination Study in Gout Subjects
Completed
NCT02246673
Ardea Biosciences, Inc.
Gout
Start: 2014-10-31
End: 2016-02-29
Updated: 2017-07-27
Phase 3
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
NCT05815901
JW Pharmaceutical
Gout
Start: 2023-03-14
End: 2025-08-31
Target: 588
Updated: 2023-04-18
Unknown Phase
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
Completed
NCT05264584
Ain Shams University
Chronic Kidney Disease stage3, Contrast-induced Nephropathy
Start: 2020-12-01
End: 2022-02-01
Updated: 2022-03-25
Related Papers
Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.
2020-09-19
5 citations
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
RMD Open
2018-04-01
13 citations
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
RMD Open
2018-02-01
39 citations